Epizyme shares slump as can­cer drug da­ta up­date dis­ap­points

An­a­lysts hate to be dis­ap­point­ed, and that’s just what Epizyme $EPZM ac­com­plished this morn­ing as it up­dat­ed its camp fol­low­ers with the lat­est da­ta on tazeme­to­stat for dif­fuse large B-cell lym­phoma.

Ini­tial­ly, ob­servers had been pleased by the 40% over­all re­sponse rate that re­searchers had been track­ing on DL­B­CL for its EZH2 in­hibitor. Then this morn­ing the com­pa­ny pro­vid­ed an up­date on their Phase II with more pa­tients in the mix, and the ORR dropped to 29%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.